AI Article Synopsis
- The GnRH antagonist-based ovarian stimulation protocol is becoming more popular, allowing the use of GnRH agonist for final oocyte maturation instead of the typical hCG trigger.
- GnRH agonist triggers help prevent ovarian hyperstimulation syndrome (OHSS) but require luteal phase support to secure pregnancy due to their rapid luteolysis.
- The review discusses optimal timing for luteal support with hCG after GnRH agonist trigger and presents guidelines for designing effective luteal phase support.
Article Abstract
Gonadotropin-releasing hormone (GnRH) antagonist-based ovarian stimulation protocol is gaining popularity. This protocol allows for the use of GnRH agonist as a trigger of final oocyte maturation, instead of the "gold standard" human chorionic gonadotropin (hCG) trigger. GnRH agonist trigger causes quick luteolysis, hence its widespread use in the context of ovarian hyperstimulation syndrome (OHSS) prevention. To secure pregnancy post GnRH agonist trigger, the luteal phase must be supplemented to counteract the luteolysis. Several luteal phase protocols post GnRH agonist trigger have been suggested, most notably based on increasing luteal luteinizing hormone (LH) activity (by adding LH or hCG). The current review aims at delineating a rationale for timing luteal support with a single hCG bolus post GnRH agonist trigger. The review also suggests a set of simple rules that must be followed when designing luteal phase support post GnRH agonist trigger.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000491088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, Synthesis, and Biological Assessment of Novel Aminobenzidazole Agonists Targeting the Stimulator of Interferon Genes Receptor Signaling Pathway for Oncology Immunotherapy.
ChemMedChem
December 2024
China Pharmaceutical University, State Key Laboratory of Natural Medicines, CHINA.
The activation of the STING-mediated signaling pathway leads to the secretion of type I interferon (IFN) and the activation of tumor-specific T cells. STING, a pattern recognition receptor located on the endoplasmic reticulum membrane of immune cells, binds with endogenous cyclic dinucleotides. STING undergoes phosphorylation, triggering the STING-TBK1-IRF3 pathway and NF-κB pathway, resulting in the release of IFN-β and other pro-inflammatory cytokines, ultimately enhancing the activation of tumor-specific T cells.
View Article and Find Full Text PDFDiscovery of a non-nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect.
MedComm (2020)
January 2025
Agonists of the stimulator of interferon genes (STING) pathway are increasingly being recognized as a promising new approach in the treatment of cancer. Although progress in clinical trials for STING agonists in antitumor applications has been slow, there is still an urgent need for developing new potent STING agonists with versatile potential applications. Herein, we developed and identified a non-nucleotide STING agonist called DW18343.
View Article and Find Full Text PDFExploring the Complex Mechanisms of Isoflavones: From Cell Bioavailability, to Cell Dynamics and Breast Cancer.
Phytother Res
December 2024
Université de Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France.
In Western countries, the increase in the consumption of soy-derived products raises the population's exposure to isoflavones. These molecules, present in many foods, have numerous effects on the body's cells, including regulation of the transcription and epigenetics, cell signaling, cell cycle, cell growth, apoptosis, and oxidative stress. However, despite the multitude of studies conducted, on these compounds, it remains difficult to draw definitive conclusions regarding their safety or dangerousness in the diet.
View Article and Find Full Text PDF5' terminal nucleotide determines the immunogenicity of IVT RNAs.
Nucleic Acids Res
December 2024
International Institute of Molecular and Cell Biology in Warsaw, Ksiecia Trojdena 4, 02-109 Warsaw, Poland.
In vitro transcription (IVT) is a technology of vital importance that facilitated the production of mRNA therapeutics and drove numerous breakthroughs in RNA biology. T7 polymerase-produced RNAs can begin with either 5'-triphosphate guanosine (5'-pppG) or 5'-triphosphate adenosine (5'-pppA), generating potential agonists for the RIG-I/type I interferon response. While it is established that IVT can yield highly immunogenic double-stranded RNA (dsRNA) via promoterless transcription, the specific contribution of initiating nucleosides to this process has not been previously reported.
View Article and Find Full Text PDFThe adjuvant effect of manganese on tuberculosis subunit vaccine Bfrb-GrpE.
NPJ Vaccines
December 2024
Key Laboratory of Blood-stasis-toxin Syndrome of Zhejiang Province, School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Protein subunit vaccines, lacking pathogen-associated molecular patterns that trigger immune responses, rely on adjuvants to induce robust immune responses against the target pathogen. Thus, selection of adjuvants plays a crucial role in the design of protein subunit vaccines. Recently, there has been growing interest in utilizing cGAS-STING agonists as vaccine adjuvants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!